Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would "maximize the potential of Metsera's complementary portfolio and capabilities."
Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would "maximize the potential of Metsera's complementary portfolio and capabilities."
